Eli Lilly has no plans to ease up on R&D spending. Meanwhile, Danaher continues to await an 'inflection point,' while GE Healthcare touts its AI opportunity.
from US Top News and Analysis https://ift.tt/ec2WrqM
https://ift.tt/zqWsrXm
from US Top News and Analysis https://ift.tt/ec2WrqM
https://ift.tt/zqWsrXm
Comments
Post a Comment